LAMB1

LAMB1 encodes the β1 chain of laminin, a multidomain basement membrane glycoprotein that serves as a haptotactic ligand for integrin receptors and transduces extracellular matrix signals into diverse intracellular pathways including Rac1/F-actin polarization, FAK–MEK1/2, Wnt/β-catenin, and NF-κB/HK2 (PMID:41206867, PMID:36519511, PMID:40221061, PMID:39920513). Vascular LAMB1 provides a guidance cue sensed by integrin α6 to direct microglial precursor migration into the retina, while in other contexts it promotes angiogenesis via VEGFA upregulation and modulates complement C3-dependent antiviral responses (PMID:41206867, PMID:40221061, PMID:40237496). LAMB1 transcription is regulated by ERK/c-Jun and cAMP/PKA pathways, and its mRNA is stabilized by DDX24–nucleolin binding, whereas miR-124-5p and miR-365-1-5p suppress its expression post-transcriptionally (PMID:33435161, PMID:9419418, PMID:35763670, PMID:24497408). Loss-of-function and dominant missense or C-terminal truncation mutations in LAMB1 cause leukoencephalopathy, cerebral small vessel disease, and dystonia-like movement disorders due to failed basement membrane secretion and disrupted CNS extracellular matrix integrity (PMID:26705335, PMID:34606115, PMID:40237576).

1. 1987 High

   Determining the full primary structure and chromosomal location of LAMB1 established its multidomain architecture—cysteine-rich repeats, globular regions, and helical segments—providing the first molecular framework for understanding laminin β1 chain function.

   Evidence cDNA cloning, sequence analysis, somatic cell hybrid mapping, and in situ hybridization localized the gene to chromosome 7q22

   PMID:3611077

   Open questions at the time

   • No three-dimensional structure of the full-length protein
   • Functional significance of individual domain repeats not tested
2. 1997 Medium

   Identification of cAMP/PKA and cis-regulatory elements controlling LAMB1 transcription revealed that its expression is actively regulated rather than constitutive, with tissue-specific promoter elements directing expression in kidney, mammary gland, and germ cells.

   Evidence Dominant-negative PKA, CAT reporter assays, EMSA in cell lines; transgenic LAMB1 promoter-lacZ mice showing tissue-specific reporter expression

   PMID:9419418 PMID:9447707

   Open questions at the time

   • Identity of the C2 motif-binding transcription factor not determined
   • Promoter elements for CNS expression not mapped
3. 2014 Medium

   Demonstrating that miR-124-5p directly suppresses LAMB1 protein and that LAMB1 knockdown phenocopies miR-124-5p restoration in glioma established LAMB1 as a post-transcriptionally regulated oncogenic effector in brain tumors.

   Evidence miR-124-5p restoration and direct LAMB1 knockdown in glioma cells with parallel reduction in proliferation, colony formation, and in vivo tumor growth

   PMID:24497408

   Open questions at the time

   • Direct miRNA-target binding site validation (e.g., luciferase reporter with mutant 3′-UTR) not shown in this study
   • Downstream signaling pathway mediating LAMB1-driven glioma growth not identified
4. 2015 High

   A dominant missense Lamb1 mutation causing dystonia-like movement disorder in mice linked LAMB1 to CNS circuit function, showing that basement membrane disruption in the cerebellum leads to aberrant Purkinje cell and deep cerebellar nucleus output.

   Evidence SNP mapping, exome sequencing of mouse mutant; in vivo cerebellar electrophysiology and EMG co-contraction analysis in awake mice

   PMID:26705335

   Open questions at the time

   • Precise mechanism by which the missense mutation disrupts laminin trimer assembly or ECM integration not resolved
   • Whether the same circuit dysfunction occurs in human patients unknown
5. 2021 Medium

   Two advances clarified LAMB1's transcriptional regulation and its role in human disease: ERK/c-Jun was shown to directly activate LAMB1 transcription via promoter binding, and C-terminally truncated LAMB1 variants were found trapped in the cytosol of patient fibroblasts, causing cerebral small vessel disease and leukoencephalopathy.

   Evidence ChIP of c-Jun on LAMB1 promoter with ERK inhibitor in gastric cancer cells; western blotting with N- and C-terminal antibodies in patient fibroblasts plus gene-based collapsing analysis of exome data

   PMID:33435161 PMID:34606115

   Open questions at the time

   • Whether cytosol-trapped truncated LAMB1 exerts toxic gain-of-function versus simple loss-of-function not distinguished in patient cells
   • Relationship between ERK/c-Jun regulation and CNS-specific LAMB1 expression unexplored
6. 2022 High

   Identification of DDX24–nucleolin as a complex that binds LAMB1 mRNA (nt 618–624) and stabilizes it revealed a dedicated post-transcriptional axis controlling LAMB1 abundance, operating downstream of RFX8 transcription.

   Evidence RNA immunoprecipitation, co-immunoprecipitation of DDX24-nucleolin, mRNA stability assays, and in vivo HCC tumor model

   PMID:35763670

   Open questions at the time

   • Structural basis of DDX24 recognition of the 618–624 motif unknown
   • Whether DDX24-nucleolin regulation of LAMB1 operates outside hepatocellular carcinoma not tested
7. 2023 Medium

   LAMB1 was shown to physically interact with FAK and transduce substrate stiffness into MEK1/2 signaling, establishing it as a direct mechanosensory input to focal adhesion signaling beyond a passive structural role.

   Evidence Co-immunoprecipitation of LAMB1-FAK, substrate stiffness modulation on polydimethylsiloxane, western blotting in odontoblast-like cells

   PMID:36519511

   Open questions at the time

   • Binding interface between LAMB1 and FAK not mapped
   • Whether this mechanotransduction operates in other cell types not established
8. 2025 Medium

   A series of studies in 2025 expanded LAMB1's functional repertoire: vascular LAMB1 acts as a haptotactic gradient for integrin α6-expressing microglial precursors via Rac1/F-actin; it activates Wnt/β-catenin to drive VEGFA in endothelial cells; it signals through NF-κB/HK2 to promote aerobic glycolysis in glioma; it modulates complement C3 antiviral responses; and Drosophila modeling confirmed blood-brain barrier function and suggested dominant gain-of-function for C-terminal truncation variants.

   Evidence Zebrafish/mouse endothelial-specific knockout with live imaging; siRNA knockdown in HUVECs with Wnt activator rescue; Seahorse metabolic assays with NF-κB inhibitor in glioma cells; ceRNA axis characterization in rotavirus-infected cells; Drosophila BBB-specific knockdown and HEK293T secretion assays

   PMID:39920513 PMID:40221061 PMID:40237496 PMID:40237576 PMID:41206867

   Open questions at the time

   • Whether LAMB1 engages these diverse pathways simultaneously or in a context-dependent manner is unclear
   • Structural basis for how a single ECM molecule activates Wnt, NF-κB, and integrin–Rac1 pathways not resolved
   • In vivo validation of NF-κB/HK2 and Wnt/VEGFA axes beyond tumor xenograft or HUVEC systems is lacking

• Key unresolved questions include: (1) how LAMB1 assembles with α and γ chains and how disease-causing mutations perturb heterotrimer secretion at a structural level; (2) whether the diverse signaling outputs (Rac1, FAK-MEK, Wnt, NF-κB, complement C3) reflect distinct receptor-binding domains or shared integrin-mediated mechanisms; and (3) the genotype–phenotype relationship for dominant versus recessive LAMB1 alleles in human CNS disease.
• No high-resolution structure of laminin β1 or its disease-relevant mutants
• No systematic allelic series comparing gain- versus loss-of-function in a single model organism
• Receptor specificity for individual LAMB1 signaling outputs not dissected